Bicara Therapeutics Inc. (BCAX)

Price$23.18Cached quoteAs of 2026-09-04 16:23 UTC

AI: Fair-priced

Price checkThe valuation assumes meaningful success, while trial risk keeps the outcome too uncertain.

Using 65.9 million shares outstanding, the equity is worth about $1.51 billion; including 2.2 million near-zero-cost prefunded warrants raises that to roughly $1.56 billion. Against $497.3 million of cash and marketable securities, investors assign about $1.0–$1.1 billion to the drug program and organization, or roughly three times liquid resources. With no revenue and pivotal evidence pending, that recognizes encouraging early data but leaves neither an obvious bargain nor a clearly excessive valuation: Fair-priced.

Big pictureBicara can fund key trials, but losses are rising before any product sales.

Revenue remains zero. Operating cash use was $81.7 million in the first half of 2026 versus $53.7 million a year earlier, while the net loss widened to $111.6 million from $64.2 million. Free cash flow—cash left after operating and equipment spending—was about negative $81.8 million because equipment spending was only $0.1 million. The $497.3 million liquidity pool equals roughly three years of the latest annualized cash use; management guides into first-half 2029, but commercialization and expanding trials could shorten that runway.

Business strengthA strong balance sheet supports one promising drug, but concentration makes results highly fragile.

Debt was only $1.2 million and current assets of $503.8 million covered current liabilities more than eleven times at June 2026. The main asset, ficerafusp alfa, produced a 54% confirmed response rate and 25% complete response rate in the selected-dose cohort, with 31% estimated survival at three years. However, that cohort had just 28 patients and the survival comparison was retrospective, not randomized. Traditional economic cycles matter less than the 650-patient pivotal trial, whose mid-2027 interim result can sharply reset value.

What could change the storyPivotal proof could justify today’s premium, while failure would expose dilution and cash loss.

The bull case needs FORTIFI-HN01 to confirm that adding ficerafusp alfa beats pembrolizumab alone and to support accelerated approval; enrollment progress and the mid-2027 interim analysis are the clearest checks. Easier every-three-week maintenance dosing could improve adoption if FORTIFI-FLEX preserves benefit. The bear case is failed or delayed confirmation, which would leave no approved product against roughly $1.0 billion of value above liquid resources. Capital is reserved for trials and launch preparation, not dividends or buybacks. Shares outstanding rose 16% during the first half, and 2.2 million warrants plus a $120 million unused share-sale program create further dilution risk.

AI: News

Pivotal trial stayed on scheduleEnrollment remained on track, but a broad leadership handoff added uncertainty before crucial results.

On August 11, Bicara said FORTIFI-HN01 should be substantially enrolled by year-end, preserving a mid-2027 interim readout, and announced that Ryan Cohlhepp will replace Claire Mazumdar as chief executive in January 2027. It also started FORTIFI-FLEX to test less-frequent maintenance dosing. Shares closed about 14% lower that day on unusually heavy volume. The timing is factual, but the decline cannot be assigned solely to leadership changes because financial and trial updates arrived together.

Three-year survival updateLonger follow-up strengthened the drug’s promise, though the evidence still came from a small early study.

On May 21, the selected 1,500-milligram weekly dose plus pembrolizumab showed a 54% confirmed response rate, 25% complete response rate, 21.3-month median survival, and 31% estimated survival at three years among 28 patients. Bicara said the three-year rate was about double a retrospective pembrolizumab benchmark. This is encouraging but not definitive: the comparison was not randomized, so patient differences may explain part of the apparent advantage.

Cash runway extendedA large stock sale funded development through key milestones while spreading ownership across more shares.

On February 26, Bicara closed an offering of 8.58 million common shares plus prefunded warrants for 2.2 million more, raising $172.5 million before costs and about $161.8 million net. The cash supports the pivotal trial, manufacturing, and launch preparation, reducing near-term financing pressure. Existing holders paid through dilution: common shares reached 65.9 million by June, up 16% from December, before counting those nearly costless warrants.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022
Revenue	$0	$0	$0	$0
Research & development	$125.1M	$63.6M	$30.6M	$31.3M
Operating expenses	$155.6M	$82.4M	$39.9M	$37.7M
Operating income	−$155.6M	−$82.4M	−$39.9M	−$37.7M
EBITDA	−$155.5M	−$82.3M	−$39.9M	−$37.7M
Net income	−$137.9M	−$68.0M	−$52.0M	−$37.8M
Basic EPSper basic share	-$2.52	-$0.00	-$89.61	-$2.45
Diluted EPSper diluted share	-$2.52	-$0.00	-$89.61	-$2.45

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

11.01%of listed shares

RA CAPITAL MANAGEMENT, L.P.7.26M shares · Jun 30, 2026

View holders

Top 20 reported holders of BCAX
Holder	% owned
RA CAPITAL MANAGEMENT, L.P.	11.01%7.26M shares
T. Rowe Price Investment Management, Inc.	9.61%6.34M shares
Mazumdar-Shaw Kiran	≈9.53%6.28M shares
Siren, L.L.C.	8.50%5.6M shares
Biocon Ltd / Biocon Pharma Inc.	≈8.38%5.52M shares
Vestal Point Capital, LP	7.96%5.25M shares
Deep Track Capital, LP	6.22%4.1M shares
BlackRock, Inc.	5.84%3.85M shares
Jupiter Topco LLC	4.81%3.17M shares
RED TREE MANAGEMENT, LLC	4.80%3.16M shares
TPG GP A, LLC	4.57%3.01M shares
VANGUARD CAPITAL MANAGEMENT LLC	3.36%2.22M shares
STATE STREET CORP	3.11%2.05M shares
FRANKLIN RESOURCES INC	2.96%1.95M shares
PRICE T ROWE ASSOCIATES INC /MD/	2.89%1.9M shares
FMR LLC	2.87%1.89M shares
Omega Fund Management, LLC	2.76%1.82M shares
Deerfield Private Design Fund V, L.P. / DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) / Flynn James E / Deerfield Mgmt V, L.P. / Deerfield Mgmt L.P. / DEERFIELD PARTNERS, L.P.	≈2.72%1.8M shares
GEODE CAPITAL MANAGEMENT, LLC	1.76%1.16M shares
JPMORGAN CHASE & CO	1.54%1.02M shares

Percentages use 65.93M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Reported positions exceed 100% in total, so the circle shows the selected holder only.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys6$74.25M disclosed value

Sells (SEC code S)62$11.43M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
May 21, 2026Form 4 · 10b5-1	Hyep IvanChief Financial Officer	SellCommon Stock	9.2K	$20.42	$187.9K	145.4K
May 18, 2026Form 4 · 10b5-1	Mazumdar ClaireChief Executive Officer	SellCommon Stock	3.0K	$20.35	$60.6K	362.2K
May 18, 2026Form 4 · 10b5-1	Mazumdar ClaireChief Executive Officer	SellCommon Stock	12.0K	$19.96	$240.0K	365.1K
May 15, 2026Form 4 · 10b5-1	Cohlhepp RyanPresident and COO	SellCommon Stock	4.5K	$20.29	$91.3K	191.6K
May 15, 2026Form 4 · 10b5-1	Cohlhepp RyanPresident and COO	SellCommon Stock	8.0K	$20.29	$162.3K	196.1K

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about BCAX yet. Start the conversation.

Write the first post

Bicara Therapeutics Inc. (BCAX)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.